JLE

Sang Thrombose Vaisseaux

MENU

Neurosurgical emergency in a 23-year-old woman treated with rivaroxaban: how to manage anticoagulation? Volume 34, issue 3, May-June 2022

Figures


  • Figure 1.

  • Figure 2.
Authors
1 Hôpital Lariboisière (AP-HP), service d’hématologie biologique, 2, rue Ambroise Paré, 75010 Paris, France
2 Hôpital Lariboisière (AP-HP), service de neuro-radiologie, Paris, France
3 Hôpital Lariboisière (AP-HP), service de neurologie, Paris, France
4 Hôpital Bicêtre (AP-HP), service de neuro-chirurgie, 78, rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
5 UMR-S-1140 Innovations thérapeutiques en hémostase, Paris
* Tirès à part : V. Siguret

The management of patients treated with factor Xa inhibitors (rivaroxaban or apixaban) with severe bleeding is currently based on the use of hemostatic agents such as prothrombin complex concentrates (PCC) or activated PCC, as proposed by the Groupe d’intérêt sur l’hémostase péri-opératoire (GIHP). We report here the case of a neuro-chirurgical emergency involving a young patient treated with rivaroxaban at curative dose and requiring emergency reversal of anticoagulation for a rapidly evolving tetraparesis.